H.-B Yu

Dalian Maritime University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

A. Sidney Barritt

University of North Carolina at Chapel Hill

Sherief Abd‐Elsalam

Tanta University Hospital

B Kwan Law

European Foundation for the Study of Chronic Liver Failure

Ponni V. Perumalswami

University of Michigan–Ann Arbor

E‘

Ellen ‘t Hoen

University Medical Center Groningen

Renumathy Dhanasekaran

Stanford University

Quanxin Long

Indiana University – Purdue University Indianapolis

Gottfried Hirnschall

European Foundation for the Study of Chronic Liver Failure

S.-T Cheng

European Foundation for the Study of Chronic Liver Failure

Patrizia Burra

University of Padua

Cooperative Institutions

Inserm

225

European Foundation for the Study of Chronic Liver Failure

220

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

133

University College London

128

Assistance Publique – Hôpitaux de Paris

124

Chinese Academy of Sciences

113

Universitat de Barcelona

110

Istituti di Ricovero e Cura a Carattere Scientifico

108

Hospital Clínic de Barcelona

102

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer

101

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Meromorphic functions of finiteφ-order and linearq-difference equations

The Journal of Difference Equations and Applications (2021)

Janne Heittokangas Jun Wang Zhi‐Tao Wen H.-B Yu

The φ-order was introduced in 2009 for meromorphic functions in the unit disc, and was used as a growth indicator for solutions of linear differential equations. In this paper, the properties of meromorphic functions in the complex plane are investigated in terms of the φ-order, which measures the growth of functions between the classical order and the logarithmic order. Several results on value distribution of meromorphic functions are discussed by using the φ-order and the φ-exponent of convergence. Instead of linear differential equations, the applications in the complex plane lie in linear q-difference equations.

Complex plane

Logarithmic derivative

Exponent

10.1080/10236198.2021.1982919

Cite

Citations (8)

Contents

Journal of Hepatology (2022)

Patrizia Burra Frank Tacke Vlad Ratziu S Zeuzem Bruno Sangro

10.1016/s0168-8278(21)02194-2

Cite

Citations (0)

Analysis 33 patients of non-DS-AMKL with or without acquired trisomy 21 from multiple centers and compared to 118 AML patients

Hematology (2023)

Wenzhi Zhang Jianxin Dun Hui Li Jingzhen Liu Hongbo Chen

Background Acute megakaryoblastic leukemia (AMKL) without Down syndrome (non-DS-AMKL) usually a worse outcome than DS-AMKL. Acquired trisomy 21(+21) was one of the most common cytogenetic abnormalities in non-DS-AMKL. Knowledge of the difference in the clinical characteristics and prognosis between non-DS-AMKL with +21 and those without +21 is limited.Objective Verify the clinical characteristics and prognosis of non-DS-AMKL with +21.Method We retrospectively analyzed 33 non-DS-AMKL pediatric patients and 118 other types of AML, along with their clinical manifestations, laboratory data, and treatment response.Results Compared with AMKL without +21, AMKL with +21 has a lower platelet count (44.04 ± 5.01G/L) at onset (P > 0.05). Differences in remission rates between AMKL and other types of AML were not significant. Acquired trisomy 8 in AMKL was negatively correlated with the long-term OS rate (P < 0.05), while +21 may not be an impact factor. Compared with the other types of AML, AMKL has a younger onset age (P < 0.05), with a mean of 22.27 months. Anemia, hemorrhage, lymph node enlargement, lower white blood cell, and complex karyotype were more common in AMKL (P < 0.05). AMKL has a longer time interval between onset to diagnosis (53.61 ± 71.15 days) (P < 0.05), and patients with a diagnosis delay ≥3 months always presented as thrombocytopenia or pancytopenia initially.Conclusions Due to high heterogeneity, high misdiagnosis rate, and myelofibrosis, parts of AMKL may take a long time to be diagnosed, requiring repeated bone marrow punctures. Complex karyotype was common in AMKL. +21 may not be a promising indicator of a poor prognosis.

Trisomy

Acute megakaryoblastic leukemia

Trisomy 8

10.1080/16078454.2023.2231731

Cite

Citations (0)

Contents

Journal of Hepatology (2023)

Patrizia Burra Frank Tacke Vlad Ratziu S Zeuzem Bruno Sangro

10.1016/s0168-8278(23)05114-0

Cite

Citations (0)

Contents

Journal of Hepatology (2021)

Patrizia Burra Felix Tacke V Ratziu Stefan Zeuzem Bruno Sangro

10.1016/s0168-8278(21)02128-0

Cite

Citations (0)

Re-positive discharged COVID-19 patients are at low transmission risk for SARS-CoV-2 infection– a finding from recovered COVID-19 patients in Wuhan, China

Research Square (Research Square) (2020)

Sheng Wei Yeqing Tong Jiafa Liu Xuhua Guan Siquan Wang

Abstract Discharged COVID-19 patients have been found to be retested positive for SARS-CoV-2 (re-positive), which has widely raised concern among the public. We investigated the prevalence and transmission risk of re-positive cases in discharged COVID-19 patients and their SARS-CoV-2-specific antibody levels in Wuhan, China. Of 1065 discharged COVID-19 patients investigated, 518 (48.64%) patients were males; the mean age was 53.29 ± 14.91 years, with a median duration of 40 (IQR: 31–47) days since discharge. 63 patients were tested re-positive for SARS-CoV-2, with the re-positive prevalence to be 5.92% (95%CI: 4.50%-7.33%). The re-positive prevalence was higher in females (7.86%, 95%CI: 5.61%-10.12%) than that in males (3.86%, 95%CI: 2.20%-5.52%, P = 0.006). Re-positive prevalence was similar in patients tested positive and negative for IgG (6.01% vs 5.56%, P = 0.821) or IgM (6.38% vs 5.07%, P = 0.394). Illness severity and duration from illness onset to retest were not associated with the risk of positive results for SARS-CoV-2 after discharge. All 196 environmental samples collected from 49 re-positive patients were tested negative for SAR-CoV-2. Only one close contact to the re-positive patient had been tested positive for SARS-CoV-2; however, he might be a previous COVID-19 case but had not been detected before. Viral culture of 6 nasopharyngeal specimens presented no cytopathic effect of Vero E6 cells. Virus sequencing of 11 nasopharyngeal specimens indicated genomic fragments of SARS-CoV-2. 898 (84.72%) patients and 705 (66.51%) patients were tested positive for SARS-CoV-2-specific IgG and IgM, respectively. Self-report symptoms at the survey were similar, regardless of the level of antibody. All the re-positive patients and their matched non-re-positive patients were tested negative for SARS-CoV-2 four months later. These findings indicate that Testing re-positive of SARS-CoV-2 is common in discharged COVID-19 patients, but no evidence showed the transmission risk of these re-positive cases. Further isolation of recovered COVID-19 patients is unnecessary. However, only 85% recovered COVID-19 patients had SARS-CoV-2-specific antibody, which suggested discharged COVID-19 patients still had potential re-infection risk.

2019-20 coronavirus outbreak

10.21203/rs.3.rs-93844/v1

Cite

Citations (1)

Contents

Journal of Hepatology (2023)

Patrizia Burra Felix Tacke Vlad Ratziu S Zeuzem Bruno Sangro

10.1016/s0168-8278(22)03380-3

Cite

Citations (0)

Contents

Journal of Hepatology (2023)